Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Kopetz, Scott; Grothey, Axel; Yaeger, Rona; Van Cutsem, Eric; Desai, Jayesh; Yoshino, Takayuki; Wasan, Harpreet; Ciardiello, Fortunato; Loupakis, Fotios; Sang Hong, Yong; Steeghs, Neeltje; Kyrre Guren, Tormod; Arkenau, Hendrik‐Tobias; García‐Alfonso, Pilar; Pfeiffer, Per; Orlov, Sergey; Lonardi, Sara; Élez, Elena; Kim, Tae-Won; H.M. Schellens, Jan; Guo, Christina; Krishnan, Asha; Dekervel, Jeroen; K. Morris, Van; Calvo Ferrandiz, Aitana; Schmidt Tarpgaard, Line; Braun, Michael; Gollerkeri, Ashwin; Hunt Keir, Christopher; Maharry, Kati; D. Pickard, Michael; Christy‐Bittel, Janna; Anderson, Lisa; Sandor, Victor; Tabernero, Josep

doi:10.1056/nejmoa1908075

Public

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Published in New England Journal of Medicine • Sep 30, 2019

Authors:

Scott Kopetz

Axel Grothey

Rona Yaeger

Abstract

BACKGROUND: V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling. METHODS: V600E-mutated metastatic colo...

Subject

Cetuximab

Colorectal cancer

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!